Guerbet — Board/Management Information 2011

May 27, 2011

P R E S S I N F O R M A T I O N

Guerbet Board of Directors:

Appointment of a new director

Villepinte, May 27, 2011

The Annual General Meeting of Shareholders held on May 27, 2011 approved the appointment of a new independent director, Mrs. Marie-Claire Janailhac-Fritsch.

Guerbet's Board of Directors, which met on 1 March 2011 under the chairmanship of Jean-Jacques Bertrand, decided to present the candidacy of Mrs. Marie-Claire Janailhac-Fritsch to the Annual General Meeting of Shareholders.

The Board of Directors decided that Mrs. Marie-Claire Janailhac-Fritsch met the independence criteria required by the AFEP/MEDEF code of corporate governance for listed companies.

Marie-Claire Janailhac-Fritsch is a consultant for the cosmetics industry and a member of the French Directors Institute (IFA). She will be bringing her acknowledged experience in the pharmaceutical industry and the development of innovative molecules for the cosmetics market to the Board.

Members of the Board of Directors:

• Jean-Jacques Bertrand*, Chairman of the Board of Directors
• Bernard Massiot, CEO
• Philippe Biju-Duval
• Jacques Biot*, Chairman and CEO of JNB-Développement SA
• Vincent Dagommer, Head of Industrial Control, Europe at Novartis (OTC business)
• Olivier Guerbet, Manager at KEOSYS SAS, Manager at ADS (sarl)
• Marie-Claire Janailhac-Fritsch*
• Christian Louvet

*Independent directors

Dr Michel Guerbet is the Honorary Chairman of the Guerbet company.

About Marie-Claire Janailhac-Fritsch

Madame Janailhac-Fritsch, who graduated from the highly-rated Hautes Etudes Commerciales (H.E.C) Business School in 1978, has professional experience stretching back more than thirty years, including ten years in the pharmaceutical industry, from 1978 to 1987.

Since 1987 Mrs. Janailhac-Fritsch has worked in the cosmetics industry and has created a number of start-ups having developed new, particularly innovative molecules in the cosmetics sectors, which she chaired before selling them on to a Canadian chemicals and pharmaceuticals group.

Since 2003 Mrs. Janailhac-Fritsch has been a consultant in the cosmetics field and her recent achievements include:

• setting up spas in Japan for French brands (Cosmetics/Nutrition & Health)
• research for and a conference on organic cosmetics for an international Japanese group
• complete repositioning of a French cosmetic range distributed in pharmacies
• marketing and distribution of a range of nutritional & food complement products for a Chinese group in Europe: registration and product files, positioning, sales force training, communications.

Mrs. Janailhac-Fritsch is Chairman of the Amis du Théâtre du Châtelet, a charitable role.

About Guerbet

Guerbet is the only pharmaceutical group totally dedicated to medical imaging on the world market. It has a full range of X-ray, MRI and nuclear medicine imaging products to enhance overall patient care. Its products facilitate diagnosis and the preparation of treatment strategies for major pathologies (cardiovascular diseases, cancers, inflammatory and degenerative diseases).

To discover new products and ensure its future development, Guerbet devotes significant resources to R&D every year: 210 staff and a sum equivalent to 11% of its sales. The programs on MRI and nuclear medicine modalities are central to Guerbet's research priorities.

Guerbet has a strong presence in Europe with a market share of 25% and is developing its presence in the United States, South America and Asia.

Guerbet, listed on the Euronext Paris Eurolist (compartment B), posted sales of €352 million in 2010 with a total headcount of 1300.

For more information on Guerbet, please go to www.guerbet.com.

Press contacts: Anne-Laure Delasalle, VP Communications & Image

Tel: + 33 1 45 91 50 03

anne-laure.delasalle@guerbet-group.com